InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.560 0.552 (6,900%)+
Announcement
Release
30 Jan 2026 10:04AM
Price at Release
$0.008
Full Release
download
Summary
Alterity Therapeutics Limited released its Appendix 4C Quarterly Cash Flow Report for the second quarter of FY26, ending 31 December 2025. The report highlights strengthened Phase 2 data for ATH434 in Multiple System Atrophy (MSA), with regulatory planning advancing for a pivotal Phase 3 program. The company is preparing for an End-of-Phase-2 meeting with the FDA in mid-2026 and is in discussions with potential partners to explore non-dilutive pathways for Phase 3 funding. As of the end of the quarter, Alterity's cash position was A$49.2 million, providing a robust foundation for ongoing regulatory, clinical, and commercial efforts. Operating cash outflows for the quarter amounted to A$5.28 million, and payments to related parties totaled A$705k. The company remains focused on advancing ATH434 toward Phase 3 trials, enhancing strategic partnerships, and maintaining financial strength.
Key Points
  • ATH434 Phase 2 data for MSA strengthened.
  • Regulatory planning for Phase 3 with FDA underway.
  • Cash balance of A$49.2 million at 31 December 2025.
  • Operating cash outflows of A$5.28 million for the quarter.
  • Payments to related parties amounted to A$705k.
  • Focused on strategic partnerships and maintaining financial strength.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.